GDF11
Growth/differentiation factor 11
Written by Aaron CuhaReviewed Sep 2026
Also known as: GDF-11, BMP11, BMP-11
The young blood factor. Two famous 2013 and 2014 papers said it declines with age and rejuvenates. The human assay built to measure it properly found it does not decline, and that higher levels track with frailty.
Overview
GDF11 is the compound behind the young blood story. In 2013 a Cell paper identified it as a circulating factor that falls with age and whose restoration reversed age-related cardiac enlargement in mice. In 2014 a Science paper reported it reversed age-related skeletal muscle dysfunction. Those two results launched a decade of consumer interest and a great deal of supplement and clinic marketing.
Then it was measured properly. GDF11 and myostatin differ by only eleven amino acids in their mature signalling domains, which means an antibody raised against one will usually detect the other. When a group built a mass spectrometry assay that separates them on unique sequence features and ran it on humans, the picture inverted: it is myostatin, not GDF11, that declines with age in men, neither declines in women, and people with HIGHER GDF11 were more likely to be frail and diabetic.
This page reports the dispute rather than settling it, because it is not settled. What it will not do is repeat the 2013 headline as though the last decade did not happen.
Mechanism of action
Signals through activin type II receptors and SMAD2/3, the same axis as myostatin, and is more potent than myostatin at inducing SMAD2 phosphorylation in myocardium. That receptor sharing plus the near-identical mature domain is not a curiosity: it is the direct cause of the measurement dispute, because reagents and assays struggle to tell the two apart.
Human evidence
One measurement study and no trials. Nobody has ever given GDF11 to a human in a published trial. The human evidence that exists is about what GDF11 levels do and what they correlate with, and it points away from the famous claim.
- Using an assay specific enough to separate GDF11 from myostatin, GDF11 did not decline with age. Myostatin declined in men and neither declined in women.
- In older adults with severe aortic stenosis, higher GDF11 was associated with frailty, diabetes and prior cardiac conditions.
- After valve replacement surgery, higher baseline GDF11 was associated with rehospitalisation and multiple adverse events.
- No human has been administered GDF11 in a published trial, for any indication.
What this does not tell you: The human data are observational and come substantially from one group and one cardiac surgery cohort, which is a specific and unwell population. They establish that GDF11 does not behave the way the 2013 story requires. They do not establish that GDF11 is harmful, and they cannot, because association in a sick cohort is not causation.
Reading the research record
GDF11 is the clearest antibody-specificity cautionary tale in ageing biology, and it is worth understanding as a general lesson rather than a fact about one molecule. GDF11 and myostatin differ by eleven amino acids in the part that does the signalling. If your reagent cannot tell them apart, then a measured decline in one can be a decline in the other, and a rejuvenation result can be a story about the wrong protein.
That is not a hypothetical here. The rebuttal paper states plainly that the reagents used in the original work were not GDF11-specific, and the group that built a specificity-controlled mass spectrometry assay found the age relationship running the other way in humans.
Where the field actually stands is more interesting than either camp's headline. Exogenous GDF11 does appear to improve physiology in several animal disease models, including cardiac fibrosis and experimental stroke. So the molecule may well do something useful. What has not survived is the specific claim that made it famous: that GDF11 falls with age and topping it back up rejuvenates. Anything sold to you on that premise is being sold on a 2013 paper and a decade of contradiction.
The evidence, charted
Fig. 1 · evidence composition
1of 6 citations (17%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2013 to 2023, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2016
Quantification of GDF11 and myostatin in human aging and cardiovascular disease
The most important citation on this page. A mass spectrometry assay that resolves GDF11 from myostatin on unique sequence features. Myostatin, not GDF11, declines with age in healthy men; neither declines in healthy women. In older adults with severe aortic stenosis, those with higher GDF11 were more likely to be frail and to have diabetes, and higher baseline GDF11 predicted rehospitalisation and adverse events after valve replacement.
Cell Metabolism - Animal2013
Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy
Mouse, heterochronic parabiosis. The original claim: GDF11 declines with age and restoring it reversed age-related cardiac hypertrophy. This is the paper the young blood narrative rests on.
Cell - Animal2014
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Mouse. The muscle half of the original claim.
Science - Animal2015
GDF11 increases with age and inhibits skeletal muscle regeneration
The central rebuttal, from a Novartis-led group, and note the title. They report the earlier claims were not reproducible, that the reagents used to detect GDF11 were not GDF11-specific, that GDF11 trends upward with age in aged rat and human sera on a specific assay, and that GDF11 inhibited muscle regeneration in mice. Their conclusion is that GDF11 might be a target for blockade in sarcopenia, which is the opposite of the original therapeutic direction.
Cell Metabolism - Animal2015
GDF11 does not rescue aging-related pathological hypertrophy
Mouse. A direct failure to replicate the cardiac result.
Circulation Research - Review2023
GDF11 and aging biology: controversies resolved and pending
The most recent even-handed account. It states that many studies have since confirmed exogenous GDF11 can improve physiology in disease models including cardiac fibrosis, experimental stroke and disordered metabolism, while reviewing the controversies that remain open. Read it as the current state of an unfinished argument, not a verdict.
Journal of Cardiovascular Aging
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Interest is driven almost entirely by the young blood framing and by parabiosis coverage in popular media rather than by any human result.
- Products marketed as GDF11 exist and cannot be evaluated: there is no approved product, no established dose, and no human administration data of any kind to compare against.
Sources: Longevity forums and consumer coverage. Included to explain where the demand comes from, not as evidence of anything.
Frequently asked questions
Does GDF11 decline with age?
On the best available human measurement, no. An assay built to separate GDF11 from myostatin found GDF11 did not decline with age, while myostatin declined in men and neither declined in women. The original claim that it declines came from reagents that the rebuttal paper states were not GDF11-specific.
So was the young blood result wrong?
The specific mechanism attributed to GDF11 did not hold up, and the cardiac result failed to replicate. That is different from saying nothing happens in parabiosis experiments. It means GDF11 was probably not the explanation, and that the measurements underpinning the story could not distinguish it from a closely related protein.
Is GDF11 good or bad, then?
Unresolved, and the honest answer has two halves. In humans, higher GDF11 tracked with frailty and worse surgical outcomes in a cardiac cohort. In animal disease models, giving GDF11 has improved cardiac fibrosis, stroke and metabolic outcomes in several studies. Those can both be true. Nobody has tested it in a person.
Can I buy it?
Products exist and there is no way to evaluate them. There is no approved GDF11 product, no established human dose, and no published human administration data of any kind.